TopgOptions

ARDS upside potential

做多
NASDAQ:ARDS   None
ARDS Aridis Pharmaceuticals has 2 Phase 3 Clinical Trials for 2022, one Phase 2a study, a fully human monoclonal antibody (mAb) cocktail against COVID and a funding from the Gates Foundation to support development of inhaled formulation technology to deliver cost-effective monoclonal antibodies against influenza and COVID-19.

And the Market Cap is only 23.892Mil.

In my opinion this stock can double in trice anytime, their pipeline is highly undervalued.

免责声明

这些信息和出版物并不意味着也不构成TradingView提供或认可的金融、投资、交易或其它类型的建议或背书。请在使用条款阅读更多信息。